Ethical and Practical Considerations for an Agreement to Ensure Equitable Vaccine Access; Comment on “More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry’s Role in Widening the Access Gap”

Document Type : Commentary


Instituto de Investigaciones Filosóficas, Universidad Nacional Autónoma de México, Ciudad Universitaria, Mexico City, Mexico


This paper discusses the potential of an international agreement to ensure equitable vaccine distribution, addressing the failures witnessed during the COVID-19 pandemic. COVAX was unable to prevent vaccine monopolization and unequal distribution, which led to significant disparities in vaccination rates and avoidable deaths. Any future agreement on equitable vaccine distribution must address ethical and practical issues to ensure global health equity and access. The proposed agreement should recognize healthcare as a human right and consider vaccines beyond mere commodities, emphasizing the social responsibility of pharmaceutical companies to prioritize affordability, availability, and accessibility, particularly for low-income countries (LICs). Voluntary licensing agreements are suggested as a means to enhance access to essential medicines. The paper also outlines the necessity of international cooperation, with robust compliance mechanisms, to effectively enforce such an agreement and mitigate future health crises. 


  1. Dyer O. COVID-19: countries are learning what others paid for vaccines. BMJ. 2021;372:n281. doi:1136/bmj.n281
  2. Bollyky TJ, Bown CP. The tragedy of vaccine nationalism: only cooperation can end the pandemic. Foreign Aff. 2020;99(5):96-108.
  3. Moore S, Hill EM, Dyson L, Tildesley MJ, Keeling MJ. Retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic. Nat Med. 2022;28(11):2416-2423. doi:1038/s41591-022-02064-y
  4. Mathieu E, Ritchie H, Rodés-Guirao L, et al. Coronavirus Pandemic (COVID-19). Accessed April 23, 2024.
  5. Borges LC, Zeferino de Menezes H, Crosbie E. More pain, more gain! The delivery of COVID-19 vaccines and the pharmaceutical industry's role in widening the access gap. Int J Health Policy Manag. 2022;11(12):3101-3113. doi:34172/ijhpm.2022.6942
  6. World Health Organization (WHO). Revised Draft of the Negotiating Text of the WHO Pandemic Agreement. Accessed April 19, 2024.
  7. Emanuel EJ, Buchanan A, Chan SY, et al. What are the obligations of pharmaceutical companies in a global health emergency? Lancet. 2021;398(10304):1015-1020. doi:1016/s0140-6736(21)01378-7
  8. Médecins Sans Frontières Access Campaign. Voluntary Licenses and Access to Medicines: Médecins Sans Frontières Technical Briefing Document. 2020. Accessed April 22, 2024.
  9. Gore C, Morin S, Røttingen JA, Kieny MP. Negotiating public-health intellectual property licensing agreements to increase access to health technologies: an insider's story. BMJ Glob Health. 2023;8(9):e012964. doi:1136/bmjgh-2023-012964
  10. Emanuel EJ, Persad G, Kern A, et al. An ethical framework for global vaccine allocation. Science. 2020;369(6509):1309-1312. doi:1126/science.abe2803
  11. Ortiz-Millán G. How populism affects bioethics. Camb Q Healthc Ethics. 2024:1-15. doi:1017/s0963180124000161
  12. Scholz M, Smith NC, Riegler M, Burton A. Public health and political corporate social responsibility: pharmaceutical company engagement in COVAX. Bus Soc. 2024;63(4):813-850. doi:1177/00076503231158600
  13. Kavanagh MM, Wenham C, Massard da Fonseca E, et al. Increasing compliance with international pandemic law: international relations and new global health agreements. Lancet. 2023;402(10407):1097-1106. doi:1016/s0140-6736(23)01527-1
  14. Singer PA. Replenishment of the Global Fund: global solidarity needed. Lancet. 2016;388(10050):1139-1141. doi:1016/s0140-6736(16)31601-4
  15. Kaddar M, Furrer E. Are current debt relief initiatives an option for scaling up health financing in beneficiary countries? Bull World Health Organ. 2008;86(11):877-883. doi:2471/blt.08.053686
  16. Hey E. The Principle of Common but Differentiated Responsibilities. UN Legal. Accessed April 19, 2024.
  17. Fu X, Buckley PJ, Sanchez-Ancochea D, Hassan I. The world has a unique opportunity: accelerating technology transfer and vaccine production through partnerships. J Int Bus Policy. 2022;5(3):406-415. doi:1057/s42214-021-00124-7
  18. Shinh R. Pandemic Bonds: What Are They and How Do They Work? Actuaries in Government. March 2, 2021. Accessed April 22, 2024.
  19. Humphrey C, Prizzon A. Scaling Up Multilateral Bank Finance for the COVID-19 Recovery. ODI; 2020. Accessed April 19, 2024.
  20. Gavi, The Vaccine Alliance. Analysis Paper–A Preliminary Assessment of COVAX’s Impact in Lower-Income Countries. Gavi, The Vaccine Alliance; 2023.
  21. A patent waiver on COVID vaccines is right and fair. Nature. 2021;593(7860):478. doi:1038/d41586-021-01242-1
  22. Rouw A, Wexler A, Kates J, Toole K, Britto A, Katz R. Assessing the Role of Treaties, Conventions, Institutions, and Other International Agreements in the Global COVID-19 Response: Implications for the Future. Global Health Policy. 2023. Accessed April 19, 2024.
  23. Hoffman SJ, Baral P, Rogers Van Katwyk S, et al. International treaties have mostly failed to produce their intended effects. Proc Natl Acad Sci U S A. 2022;119(32):e2122854119. doi:1073/pnas.2122854119

Articles in Press, Corrected Proof
Available Online from 28 April 2024
  • Receive Date: 01 April 2024
  • Revise Date: 23 April 2024
  • Accept Date: 27 April 2024
  • First Publish Date: 28 April 2024